Neurobehavioral and neuroprotector effects of caffeine in animal models

Dina Villanueva-García • Daniel Mota-Rojas • Agatha Miranda-Cortés • Patricia Mora-Medina • Ismael Hernández-Avalos • Alejandro Casas-Alvarado • Adriana Olmos-Hernández • Julio Martínez-Burnes

D Villanueva-García
Division of Neonatology, National Institute of Health Hospital Infantil de México Federico Gómez, Mexico City, Mexico.

D Mota-Rojas (Corresponding author) • A Casas-Alvarado
Neurophysiology, Behavior, and Animal Welfare Assessment, Department of Animal Production and Agriculture (DPAA), Universidad Autónoma Metropolitana (UAM) Xochimilco Campus, 04960, Mexico City, Mexico.

email: dmota@correo.xoc.uam.mx

A Miranda-Cortés • I Hernández-Avalos
Clinical Pharmacology and Veterinary Anaesthesia. Department of Biological Science. Universidad Nacional Autónoma de México (UNAM), FESC, 54714, Mexico.

P Mora-Medina
Livestock Science Department, Universidad Nacional Autónoma de México (UNAM), Facultad de Estudios Superiores Cuautitlán, 54714, State of Mexico, Mexico.

A Olmos-Hernández
Bioterio y Cirugía Experimental, National Rehabilitation Institute “Luis Guillermo Ibarra Ibarra” (INRLGII), Secretaría de Salud (SSA), Mexico City, Mexico.

J Martínez-Burnes
Graduate and Research Department, Facultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Tamaulipas, Victoria City, Tamaulipas, Mexico.

Received: June 29, 2020 • Accepted: July 17, 2020 • Published Online: August 16, 2020

Abstract This review aims to analyze and contrast the neurological effects associated with the use of caffeine on neurobehavior and neuroprotection in animal models. Caffeine belongs to the group of methylxanthines that exert a direct effect on adenosine receptors associated with inhibitory or excitatory G proteins, generating modification of cyclic AMP activity and intracellular calcium flow which produces alterations in the modulation system of the neurotransmitters dopamine and glutamate. The regulation of the neurotransmission systems generates protection against the inflammation of the central nervous system, by activation of the microglia and reinforcement of the blood-brain barrier. This drug will also restore cognition or prevent memory loss in Parkinson's or Alzheimer's diseases. It is important to establish new study models in other species to assess whether the behavior of the molecule is similar and to obtain other clinical applications in its behavioral and neuroprotective effects.

Keywords: adenosine receptor, caffeine consumption, cognition, dose, hypothalamus, neurodegenerative diseases, pharmacodynamic

Introduction
Caffeine (1,3,7-trimethylxanthine) is the most widely-used psychoactive drug worldwide. It is a non-specific adenosine receptor (RA) antagonist that bonds to three RA (A1, A2a, A2b) with a preference, under normal physiological conditions, for the A1 and A2a receptors (Fredholm et al 2011). In the brain, these receptors are expressed, respectively, in the pre- and post-synaptic sites of neurons, though they are also present in astrocytes, oligodendrocytes, and microglia (Sheth et al 2014). The A2a receptor is involved in neuroinflammation, and its expression in microglial cells increases after a cerebral lesion (Ohta et al 2001).

A member of the methylxanthine group of molecules, caffeine exerts a stimulating effect on the central nervous system (CNS) (Fredholm et al 1999; Fredholm et al 2005; Villanueva-García 2011; Villanueva-García and Ibarra 2016). Caffeine readily crosses cell membranes, so when ingested it quickly reaches the CNS where it modifies cell processes, stimulates intellectual activity, inhibits sleep, or reduces fatigue (Fredholm et al 1999; Góngora et al 2005). Its mechanism can participate in neurobehavioral alterations by generating increased muscular activity and modulating cognition and anxiety (Hughes, 2016; Abu-Sa’da et al 2018; Alasmari, 2020). In the first two cases, therapeutic use benefits activities that entail intense physical performance or mental complexity (Southward et al 2018). Caffeine’s anxiogenic effect is also important because it increases alertness by stimulating key regions involved in states of panic (Price, 2005). Moreover, it has neuroprotector and cytoprotector...
effects in cases of dopamine-induced damage by regulating the levels of this neurotransmitter (Kalda et al 2006). Caffeine has also been associated with an effect that retards signs of neuronal degeneration in diseases like Parkinson’s and Alzheimer’s; effects that occur through interaction with adenosine receptors and a possible association with N-methyl-D-aspartate receptors (NMDA), which increase cognition and delay the onset of the associated signs (Diler et al 2013; Kim et al 2018).

The objective of this review is to analyze and contrast the neurological effects associated with the neurobehavioral and neuroprotective effects of the use of caffeine, in addition to discussing the potential scope of its use in animal models.

Pharmacodynamic effects of caffeine

Caffeine’s main action mechanism is the antagonism of the A1, A2, and A3 adenosine receptors present in different areas of the CNS, including the nucleus accumbens, striatum, hypothalamus, cerebral cortex, hippocampus, olfactory bulb and tubercle (Salamone and Correa, 2012; Simoes et al 2016). This antagonism participates in inhibiting or exciting the G protein (pG) by altering phosphorylation of cyclic AMP and, as a result, modifying the flow of intracellular calcium (Kolahdouzan and Hamadeh, 2016) and the systems that modulate dopamine and glutamate release (Solinas et al 2002; Villanueva-Garcia 2007; Villegas and Villanueva-Garcia 2016; Lopes et al 2019; Alasmari et al 2020). The physiological effects of caffeine depend on the density of the receptors and the region of the CNS where they are found (Figure 1).

Antagonism of the A1 and A3 receptors activates inhibitory pG. This is followed by inhibition of adenylyl cyclase, which reduces the conversion of adenosine monophosphate (AMP) to cyclic AMP, thus decreasing activation of the kinase A protein. If this molecule is not in an activated state, then phosphorylation of the calcium channels is not generated, resulting in conditions that impede the influx of this ion to the intracellular level (Kolahdouzan and Hamadeh, 2016). A2 receptors, in contrast, are associated with pG stimulators that produce an increase of adenylyl cyclase and cyclic AMP that augments the sensitivity of the calcium channels, allowing this cation to enter the cell (Kamp and Hell, 2000; Dias et al 2013) (Figure 3). The modulation of adenosine A receptors and the reduction of the activity of the adenosine kinase enzyme (Fredholm et al 1999) are responsible for generating the modulation of receptors in various pathways, as shown in Figure 2.

It has been suggested that dopamine may perform a kind of competitive action with caffeine through D2 and A2 adenosine receptors (Ferré et al 1991). In this way, the antagonism of the A2 receptors would explain the potentializing of the vasomotor effects, together with the increase of dopamine in the nucleus accumbens (El Yacoumbi et al 2000).

Volkow et al (2015) found that caffeine induced an increased affinity to receptors in the ventral striatum that explains changes in thermoregulation and metabolism in the human brain. Zheng and Hasegawa (2016) corroborated this by administering caffeine intraperitoneally to Wistar rats and observing decreases in temperature and oxygen consumption that they attributed to dopamine release.

The antagonism of A1 adenosine receptors also generates glutamate exocytosis (Kerkhofs et al 2017). Studies with rats have found a correlation between the density of A1 receptors and increased glutamate concentrations in the nucleus accumbens and posterior hypothalamus (Solinas et al 2002; John et al 2014). Although the precise mechanism that produces this exocytosis remains unknown, the theory proposed in this regard is related to the glutamate cotransporter 1 in the nucleus accumbens, which can modulate the capture of aspartate and glutamate in the A2 receptor (Das et al 2015; De Freitas et al 2016).

Neurobehavioral effect

Caffeine can generate neurobehavioral effects that include increased activity, anxiety (state of alertness), and cognition (Hughes, 2016; Abu-Sa’da et al 2018; Alasmari, 2020). These effects are closely related to the chronic consumption of this substance (Spaeth et al 2014).

Caffeine and increased activity

Caffeine has ergogenic effects that increase muscular power (Garret and Holtzman, 1994; Fisone et al 2004; Hallldner et al 2004). In human medicine, a dose of 3-13 mg kg-1 has been shown to improve physical performance in sporting activities (Sökmen et al 2008), while meta-analyses have found that moderate consumption produces significant ergogenic aid in athletic performance (Ganio et al 2009; Southward et al 2018). Volkow et al (2015), in turn, pointed out that caffeine not only generates an increase of extracellular dopamine but also increases affinity to the D2 and D3 receptors in the ventral striatum by fostering changes in thermoregulation and metabolism in the brain. This theory sustains that a competitive action which is dose-dependent may exist between the D2 dopamine and A2 adenosine receptors (Ferré et al 1991) because caffeine antagonizes the latter, thus potentializing vasomotor effects by inducing an increase of dopamine in the nucleus accumbens (El Yacoumbi et al 2000).

In other research, Marin et al (2011) observed a biphasic effect of caffeine in adolescent (37-40 days) and adult (70-74 days) Wistar rats in two experiments. In the first procedure, the rats were exposed to an environment where they were habituated to caffeine via intraperitoneal

doi.org/10.31893/jabb.20039
administration at doses of 3, 10, 30, 60, or 120 mg kg⁻¹. In the second, the rats received caffeine at doses of 30, 60, or 120 mg kg⁻¹. The authors concluded that a biphasic effect occurred characterized by stimulation of locomotion at low-to-moderate doses, but no effect, or depression of locomotion, at high doses. Greater stimulation was observed in the adolescent rats compared to the adults, while depressed locomotion was seen only in the non-habituated adults.

The dominant effect of caffeine on muscular activity is due to dopamine’s action on neuronal excitation. It is not yet possible, however, to ascertain whether this effect occurs through an increase of extracellular dopamine or an increased affinity of this neurotransmitter to its receptors. The biphasic response mentioned above means we must consider both the dose and age of individuals.

![Anatomical distribution of adenosine receptors.](image)

**Figure 1** Anatomical distribution of adenosine receptors. Their distribution in the cerebral parenchyma is key for the physiological effects of caffeine. A₁ receptors are found in high densities in the temporal cortex and hypothalamus, while A₂A receptors exist in the amygdala, hippocampus, nucleus accumbens, prefrontal cortex, and striatum.

**Anxiogenic effect**

The increased state of alertness brought on by caffeine consumption has also been related to an anxiogenic effect manifested in higher blood pressure and heart rate, nausea, and trembling, signs similar to those seen in states of fear (Charney et al 1985). In human medicine, caffeine consumption has been related to these signs and higher cortisol levels. Antagonism of the A₁ and A₂A receptors (Fredholm et al 1999) modulates the transmission of stimuli in the glial cells and CNS neurons that are involved in anxiety behavior (Ribeiro et al 2002; Hohoff et al 2010). Evidence of this has been seen in studies with mice, where deactivation of the genes related to the A₁ and A₂A adenosine receptors induces greater anxiety (Ledent et al 1997; Johansson et al 2001; Smith et al 2012). Studies have established that areas like the amygdala, prefrontal medial cortex, and mid-brain have moderate densities of A₁ and A₂A receptors. All these regions perform key functions in the processing of threats, fear, and anxiety (Svenningsson et al 1997; Rosin et al 1998; Price, 2005).

Bhattacharya et al (1997) observed a similar effect in open-field and elevated plus-maze tests with rats that were administered caffeine intraperitoneally at 10, 25, and 50 mg kg⁻¹. They concluded that the rats that received the 50 mg kg⁻¹ dose reduced their entries into, and time devoted to exploring, the open arms, as well as their social interaction with congeners and alimentation in unfamiliar environments. They concluded that chronic caffeine consumption induces behavioral effects similar to those of anxiety, through antagonism of the adenosine A₁ and A₂ receptors.

**Effects on cognition**

- [doi.org/10.31893/jabb.20039](doi.org/10.31893/jabb.20039)
One of the most contrasting effects of caffeine involves cognition or memory improvement, which is reflected in a greater capacity for attention and enhanced problem-solving (Assis et al. 2018). Studies with humans have demonstrated that doses of 0.5-4 mg kg\(^{-1}\) increase cognition by improving performance in problem-solving in working environments in a manner considered dose-dependent (McLellan et al. 2016). Studies by Angelucci et al. (2002) evaluated the effects of adenosine antagonists on learning and memory in adult Wistar rats that were given caffeine intraperitoneally 30 minutes before being trained in Morris’ water maze test. In that study, administering caffeine post-training increased memory retention at doses of 0.3-10 mg kg\(^{-1}\). Pre-training administration, in contrast, did not alter the animals’ performance either during training or on the test itself; hence, it did not foster memory acquisition. These discrepancies have been observed, as well, in other studies of cognitive performance in rodents (Pan and Chen; 2007; Soellner et al. 2009; Cognato et al. 2010).

**Figure 2** Effects of caffeine on the systems that modulate neurotransmitters. These depend on the disposition of the adenosine receptor and the dominance of the modulated neurotransmitter, so both factors influence the physiological effects observed in clinical medicine. N-methyl-D-aspartate (NMDA).

The mechanism that induces memory enhancement may be mediated by the interaction between the NMDA receptors and treatment with caffeine at low doses, which have been shown to induce memory improvement in male Wistar rats (Diler et al. 2013). Recently, Kim et al. (2018) refuted the hypothesis of interaction with the GRIN2A receptor—which functions as a subunit of NMDA—because they failed to detect any significant interaction (P = 0.47). Their findings suggest that the interaction of NMDA with caffeine consumption is not the mechanism that impedes memory dysfunction. These observations make it clear that caffeine improves cognition and memory retention, but does not induce memory acquisition, especially in older animals at low or moderate doses.

**Neuroprotector effect**

Neuroprotection through caffeine consumption has spurred special interest recently in both veterinary and human medicine that has led to the elaboration of numerous studies (e.g. Kalda et al. 2006; Brothers et al. 2010; Lopes et al. 2019). The interval during which caffeine provided neuroprotection...
in a model of mice prone to Parkinson’s disease that received caffeine at doses of 30 mg kg\(^{-1}\) pre- and post-treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (which induces neuronal lesions mediated by dopamine) showed that, whether administered before or after the dopaminergic lesion, caffeine attenuated neurotoxic effects for 10 and 30 minutes and 1 and 2 hours—but not after these intervals—through a neuroprotective effect that derives from its metabolites. The neuroprotection provided by caffeine is mediated by the dopaminergic pathway when the antagonism of the A2A dopaminergic receptors occurs (Oztas et al 2002; Kalda et al 2006).

Administering a dose of caffeine to mouse offspring at 10 days of postnatal age, posterior to an ischemic hypoxic lesion, produced neuroprotection, immunomodulation, and partial functional recovery. Improvement on the open-field behavioral test reduced the loss of white and gray matter and apoptotic cell density, accompanied by a reduction of the amoeboid microglia and the astrogliosis area, and modulation of the expression of pro-inflammatory cytokines in mice treated with caffeine, compared to a control group (Di Martino et al 2020).

The neuroprotector effects observed under caffeine administration include preventing cell damage generated by cell metabolism. This protection is not limited to the neuronal level, as Barcelos et al (2014) reported that caffeine at a dose of 6 mg kg\(^{-1}\) improved enzymatic hepatic responses in rats under conditions of high-demand exercise, suggesting that it protects cells from damage caused by oxidative stress. Lv et al (2010) reported an additional behavior of this drug in rats subjected to gradual alcohol consumption followed by treatment with various doses of caffeine (5, 10, 20 mg kg\(^{-1}\)). They observed that caffeine attenuated elevation of the enzyme aminotransferase, the inflammatory cytokines, and hepatocyte necrosis. Caffeine generated a type of cytoprotection while also retarding inflammatory effects caused by the consumption of intoxicating agents like alcohol. This effect is associated with blocking the A2A receptors and attenuation of the inflammatory response produced by oxidative stress (Leite et al 2011). A2A receptors are abundant in the nerve endings of glutaminergic cells in the striatum, cortex, basal ganglia, and brain stem (Popoli et al 1995; Sebastiao and Ribeiro, 1996; Marchi et al 2002).

In one animal model, attenuation of glutamate exocytosis impeded neuronal excitation, as seen in electroencephalographic changes in mice exposed to caffeine (Corsi et al 2000). In other cases, low doses of caffeine adequately blocked the A2A receptor, with a possible attenuation of glutamate levels accompanied by significant electroencephalographic changes (Popoli et al 2002).

In light of these observations, caffeine may be able to prevent the changes that characterize neuroinflammation (Brothers et al 2010) due to its neuroprotective effect as a dose-dependent cytoprotector. This protection is provided through both the dopaminergic and glutaminergic pathways, independently of the dose administered, but in the presence of a certain density of A2A receptors. Therefore, this receptor is in charge of the protective properties of the methylxanthines.

**Figure 3** Representation of adenosine receptor antagonism. By antagonizing the A1 or A3 receptors linked to inhibitory (pGi), caffeine produces inhibition of adenylate cyclase activity, thus impeding the conversion of monophosphate (AMP) into cyclic AMP (AMPc). This, in turn, reduces the activity of the kinase A protein (PKA), blocking the phosphorylation of Ca\(^{2+}\) channels. Antagonism of A2 receptors is associated with stimulating G proteins (pGs) that produce an increase of adenylate cyclase and cyclic AMP, which increase the sensitivity of the calcium channels to facilitate entry into the cell.

**Effects in neurodegenerative diseases**

Retrospective studies report a negative relation between caffeine consumption and the risk of suffering neurodegenerative diseases, due to antagonism of A2A receptors (El Yacoubi et al 2001; Góngora et al 2005; Kalda et al 2006). This has been explained by the possible interaction of this receptor with memory and behavioral disorders. Caffeine may perform a neuroprotector function due to the increase in extracellular glutamate (Alasmari, 2020). Instilling caffeine at concentrations of 50 µM can facilitate synaptic transmission by 40% and reduce the amplitude of long-term
potentializing by 35%, in association with phenomena of enhanced neuronal plasticity and the blocking of adenosine receptors (Lopes et al 2019).

Recently, the NMDA receptors have been related to the capacity to control the glutaminergic pathway and cerebral metabolism (Lopes et al 2019).

Another possible mechanism for impeding the development of neurodegenerative diseases entails maintaining the integrity of the blood-brain barrier through its modulation (Chen et al 2010).

Additional studies are required to establish a relation between these two phenomena and allow researchers to determine their benefits in treating neurodegenerative diseases or to replicate these effects in other species with diseases that manifest similar behaviors, such as cognitive dysfunction in canines (Dewey et al 2019).

It is evident that the use of caffeine can prevent, or retard, the signs of neurodegenerative diseases, though it is not yet clear which pathway produces the mechanism of protection against them. Hence, it is necessary to review the models used in studies of this drug in greater depth and replicate the aforementioned phenomena in other species with similar diseases.

Neurotoxic effects

Abuse in caffeine consumption can cause such health problems as a greater risk of suffering convulsions, development of arrhythmias, and a reduced hypoxic response (Ilbaek et al 2007; Vesoulis et al 2016; Van Koert et al 2018; Qian et al 2019). Studies of species like dogs and rats have demonstrated that caffeine increases neurotoxicity and makes organisms more prone to suffering convulsions (Basset et al 2014). This mechanism has been associated with increased glutamate exocytosis, which generates greater neuronal activity (Fredholm and Hedqvist, 1980; Hoexter et al 2005). The use of other methylxanthines – e.g. theophylline – has been associated with convulsions in rats (Yasuhsara and Levy; 1988), though its neurotoxic effect depends on such factors as treatment duration, interaction with other drugs, and dosage (Van Koert et al 2018; Alasmari, 2002). The latter factor has been shown to promote neurotoxicity in the granular cells of the cerebellum of rat offspring, which is significant for the onset of convulsions (Gepdiremen et al 1988). Finally, an overdose of 50 mg kg-1 induced significant neuronal death in various brain regions in rats (Kang et al 2002).

Caffeine does not affect only the neuronal structure, but can also produce alterations in the amounts of receptors derived from the antagonism of adenosine receptors, induce changes in cardiac function and growth, and even modify deoxyribonucleic acid methylation (Buscariollo et al 2014). These effects were evaluated in vitro in embryos of complete murine and isolated hearts, where it was possible to identify that caffeine reduced the normal heart rate with hypoxia, a potentially worrisome aspect that should be considered during gestation. This phenomenon occurred due to antagonism of the A1 and A2 receptors (Buscariollo et al 2011).

Although caffeine does provide potential benefits, its use and consumption can produce affectations in the long term. For this reason, it is necessary to consider subjects’ physiological status, gestation, and general state of health since, as we elucidated above, this drug can present severe interactions through antagonism of the adenosine receptors.

Behavior in addictions

One of the principle problems associated with caffeine consumption is addiction (Lee et al 2020), a situation that provokes an increase of functional brain activity due to the release of dopamine, specifically in the cortex of the nucleus accumbens, which has been identified as a key structure in reward, motivational and addictive behaviors (Griffiths and Woodson 1988; Nehlig 1999).

Studies in humans have identified that the behaviors associated with caffeine addiction include irritability, anxiety, fatigue, and altered mobility (American Psychiatric Association, 2013; Mitchell et al 2014). Concerning animals, discussions regarding the presence of these addictive behaviors are ongoing (Edwards et al 2012; Park et al 2015; Avegno and Gilpin 2019).

A recent study of male Wistar rats by Lee et al (2020) analyzed whether prolonged voluntary caffeine consumption led to compulsive ingestion. They divided the rats into three groups concerning exposure to caffeine (low, medium, high), observing compulsive consumption in the rats that received the high concentration, but not in those exposed to low or medium levels. Their study successfully identified such behaviors as irritability, anxiety, and sensitivity to pain.

According to this evidence, it may be that animals present behaviors similar to those of humans about addiction since they have cerebral structures similar to those that cause these behaviors in humans.

Perspectives for the clinical use of caffeine

Diverse clinical studies suggest potential uses of caffeine consumption or administration (Lucas et al 2011; Colella et al 2018; Franca et al 2018). Antagonism of the A1 receptors in the hippocampus (Salamone and Correa 2012) has led to the postulate that caffeine significantly reduces the risk of depression in women (Lucas et al 2011).

Caffeine may also reinforce muscular activity and enhance recognition in patients with neurocognitive deficits (Assis et al 2018). Studies with humans have corroborated improvements in performance at work or in sports (Burke, 2008; Cappelletti et al 2015). In this regard, in addition to enhancing cognition, caffeine could generate benefits for

doi.org/10.31893/jabb.20039
patients with attention deficit and hyperactivity disorders by normalizing dopamine levels (Franca et al. 2018).

A final interesting aspect that is gaining importance is using caffeine to strengthen the blood-brain barrier as a means to prevent brain damage caused by acute inflammation by activating the microglia through the A2A receptors (Colella et al. 2018). Clinical uses of caffeine in human medicine are supported by such experimental evidence. In animals, in contrast, it is necessary to establish up-to-date models for various species that suffer pathologies that may be comparable to those analyzed in humans to determine whether caffeine has the same therapeutic potential.

Final Considerations

This review analyzed and contrasted the neurological effects associated with the neurobehavioral and neuroprotector effects of caffeine, while also outlining potential clinical uses of this drug in animal models for events identified by antagonism of the A1, A2 and A3 adenosine receptors in the CNS and the modulation of neurotransmitters—mainly dopaminergic, glutaminergic and GABAmimergic—that constitute important systems in neuronal activity. This modulation of neurotransmission systems plays a key role in neuroprotection by reducing the toxicity caused by dopamine.

Recent evidence demonstrates that by regulating these neurotransmission systems it is possible to generate protection against inflammation of the CNS, where there is sufficient evidence of caffeine’s ability to restore cognition and prevent memory loss in such conditions as Parkinson’s and Alzheimer’s disease. However, it is important to develop new study models for other species to determine whether the behavior of this molecule is similar, intending to establish other clinical applications that take advantage of caffeine’s effects on behavior and neuroprotection.

Conflict of Interest

The authors declare that they have no conflict of interest.

Funding

This research did not receive any financial support.

References


doi.org/10.31893/jabb.20039


doi.org/10.31893/jabb.20039